# Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer Canonical URL: https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-appoints-carl-segerstrom-as-chief-people-officer-1598bf7e Ticker: ACAD Company: ACADIA Pharmaceuticals Inc. Source: ACADIA Pharmaceuticals Inc. Published: 2026-07-06 13:04 EST Original Source URL: https://acadia.com/media/news-releases/ ## Summary Experienced global HR leader joins Acadia to advance people strategy and support the next phase of growth Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company’s global people and culture strategy, supporting its next phase of growth as a leading neurological and rare disease company focused on advancing therapies for patients with significant unmet needs. He will serve as a member of Acadia’s executive leadership team. “Carl is a proven global leader with a strong track record of building high-performing organizations and shaping culture to enable business performance,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “His experience driving transformation in complex, science-driven organizations will be instrumental as we continue to scale and advance our mission for patients.” Carl joins Acadia with more than 25 years of experience in global human resources ## Article Body Home News & Media News Releases Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer July 6, 2026 General —Experienced global HR leader joins Acadia to advance people strategy and support the next phase of growth SAN DIEGO—(BUSINESS WIRE)— Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company’s global people and culture strategy, supporting its next phase of growth as a leading neurological and rare disease company focused on advancing therapies for patients with significant unmet needs. He will serve as a member of Acadia’s executive leadership team. “Carl is a proven global leader with a strong track record of building high-performing organizations and shaping culture to enable business performance,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “His experience driving transformation in complex, science-driven organizations will be instrumental as we continue to scale and advance our mission for patients.” Carl joins Acadia with more than 25 years of experience in global human resources leadership across the biopharmaceutical industry, including a 17-year career at Merck. Most recently, he served as Senior Vice President, Human Resources at Merck’s Human Health Division, supporting a $50+ billion global business spanning 80 countries. Over the course of his career at Merck, Carl has held a range of senior leadership roles, including Chief Talent Officer, where he was responsible for global talent strategy, executive succession planning, leadership development, and workforce transformation. Earlier in his career, he held human resources leadership roles at Pharmacia, Schering-Plough and Pfizer across multiple international markets. Carl brings deep expertise in organizational transformation and talent strategy across global organizations, including leading large-scale workforce capability shifts, digital and AI-enabled initiatives, and global operating model redesign. He has also led talent acquisition organizations hiring more than 10,000 employees annually and overseen workforce planning across globally diverse teams. “I am excited to join Acadia at this important stage of growth,” said Mr. Segerstrom. “The company’s focus on serving patients and advancing innovation is compelling, and I look forward to partnering with the leadership team to strengthen our culture, develop talent, and support the company’s continued success.” Carl holds a Master’s degree in Human Resources Management from Uppsala University in Sweden and has completed executive development programs at institutions including Harvard Business School and the University of Chicago Booth School of Business. About Acadia Pharmaceuticals Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X . Source: Acadia Pharmaceuticals Inc. ## Recent Company News - 2026-07-20 13:05 EST — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c) — Source: ACADIA Pharmaceuticals Inc. - 2026-07-15 20:05 EST — [Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-to-announce-second-quarter-2026-financial-results-on-augu-562a4f56) — Source: ACADIA Pharmaceuticals Inc. - 2026-07-06 13:04 EST — [Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-appoints-carl-segerstrom-as-chief-people-officer-1598bf7e) — Source: ACADIA Pharmaceuticals Inc. - 2026-06-26 10:49 EST — [DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP](https://biopharmsignal.com/news/ACAD/daybu-trofinetide-recommended-for-approval-in-the-european-union-by-chmp-b5e699e2) — Source: ACADIA Pharmaceuticals Inc. - 2026-05-06 20:05 EST — [Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-reports-first-quarter-2026-financial-results-and-reaffirm-f524e802) — Source: ACADIA Pharmaceuticals Inc. ## Related News - 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47) - 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) - 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f) - 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c) - 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)